|
Home > Archive > Medicine laboratory > February 2006 > Viscosity? / pulse pressure / inflammation?
You are viewing an archived Text-only version of the thread.
To view this thread in it's original format and/or if you want to reply to
this thread please [click here]
| Author |
Viscosity? / pulse pressure / inflammation?
|
|
| ironjustice@aol.com 2006-02-25, 8:48 pm |
| Eur J Endocrinol. 2005 Nov;153(5):687-91. Related Articles, Links
The tumour necrosis factor (TNF)-alpha system is activated in
accordance with pulse pressure in normotensive subjects with type 1
diabetes mellitus.
Gonzalez-Clemente JM, Gimenez-Perez G, Richart C, Broch M, Caixas A,
Megia A, Gimenez-Palop O, Simon I, Mauricio D, Vendrell J.
Department of Diabetes, Endocrinology and Nutrition, Hospital de
Sabadell, Sabadell, Spain. jmgonzalez@cspt.es
OBJECTIVE: Pulse pressure (PP) and inflammation are important
predictors of cardiovascular disease (CVD), even in the normotensive.
The age-related increase in PP can be diagnosed up to 20 years earlier
in subjects with type 1 diabetes mellitus (T1DM) than in the general
population. Some evidence suggests that PP can stimulate inflammation.
Our aim was to study the relationship between PP and plasma
inflammatory proteins in normotensive subjects with T1DM. DESIGN: This
was a cross-sectional study of a group of normotensive (<140/80 mmHg)
subjects diagnosed with T1DM 14 years before. None of them had
clinically proven CVD or inflammatory conditions or were on
antiplatelet, antihypertensive, anti-inflammatory or lipid-lowering
treatment. METHODS: The following information was recorded: sex, age,
body-mass index (BMI), waist-to-hip ratio (WHR), systolic blood
pressure (SBP), diastolic blood pressure (DBP), PP, mean blood pressure
(MBP), smoking, alcohol intake, insulin dose, lipid profile, HbA1c,
microvascular complications, and plasma concentrations of soluble
receptor types 1 and 2 of tumour necrosis factor (TNF)-alpha (sTNFR1
and sTNFR2, respectively), interleukin-6, C-reactive protein,
adiponectin and leptin. RESULTS: A total of 112 subjects were evaluated
(aged 27.4+/-6.6 years, 52.7% women, BMI: 20.4+/-2.7 kg/m2, WHR:
0.82+/-0.09, SBP: 112+/-12 mmHg, DBP: 68+/-9 mmHg, PP: 45+/-9 mmHg,
MBP: 82+/-9 mmHg, HbA1c: 8.2% (7.3-9.0%), 41.1% microvascular
complications). After adjusting for potential confounders, only
inflammatory markers of the TNF-alpha system correlated significantly
with PP (Pearson correlation coefficient between sTNFR1 and PP: r =
0.215, P = 0.030; and between PP and sTNFR2: r = 0.238, P = 0.020).
CONCLUSION: In normotensive subjects with T1DM after 14 years of
diagnosis, the activation of the TNF-alpha system is positively
associated with PP levels. This finding might suggest a pathogenic role
of the TNF-alpha system in the development of cardiovascular disease in
T1DM.
PMID: 16260427 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
| |
| ironjustice@aol.com 2006-02-25, 8:48 pm |
|
J Neuroimmunol. 2003 Jun;139(1-2):150-4. Related Articles, Links
Leptin as a marker of multiple sclerosis activity in patients treated
with interferon-beta.
Batocchi AP, Rotondi M, Caggiula M, Frisullo G, Odoardi F, Nociti V,
Carella C, Tonali PA, Mirabella M.
Institute of Neurology, Catholic University, Largo Gemelli 8, 00168,
Rome, Italy. annapaola_b@hotmail.com
The role of leptin was investigated in relapsing-remitting multiple
sclerosis (MS). Control and MS patients showed comparable baseline
serum leptin levels. During the first year of IFNbeta-1a treatment,
leptin significantly decreased since 2 months after starting therapy in
11 patients who had no relapses. A significant decrease in IL12/IL10
ratio was observed in this group of patients only after 1 year of
treatment. An increase of leptin was observed before the first clinical
exacerbation in 13 relapsing patients. Leptin may play a pathogenic
role in MS and can be a useful marker of disease activity and response
to therapy.
PMID: 12799033 [PubMed - indexed for MEDLINE]
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
| |
| ironjustice@aol.com 2006-02-25, 8:48 pm |
| Acetazolamide: a treatment for chronic mountain sickness.
Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O,
Bienvenu A, Lasne F, Moutereau S, Le=F3n-Velarde F
Am J Respir Crit Care Med. 2005 Dec 1; 172(11): 1427-33
RATIONALE: Chronic mountain sickness or Monge's disease is
characterized by an excessive polycythemia in high-altitude dwellers,
with a prevalence of 5 to 18% above 3,200 m. To date, no pharmacologic
treatment is available. OBJECTIVES: We evaluated the efficacy of
acetazolamide in the treatment of chronic mountain sickness and the
importance of nocturnal hypoxemia in its pathophysiology. METHODS: A
double-blind placebo-controlled study was performed in three groups of
patients from Cerro de Pasco, Peru (4,300 m), treated orally for 3
weeks with placebo (n =3D 10), 250 mg of acetazolamide (n =3D 10), or 500
mg of acetazolamide (n =3D 10), daily. RESULTS: Acetazolamide decreased
hematocrit by 7.1% (p < 0.001) and 6.7% (p < 0.001), serum
erythropoietin by 67% (p < 0.01) and 50% (p < 0.001), and serum soluble
transferrin receptors by 11.1% (p < 0.05) and 3.4% (p < 0.001), and
increased serum ferritin by 540% (p < 0.001) and 134% (p < 0.001), for
groups treated with 250 and 500 mg of acetazolamide, respectively.
Acetazolamide (250 mg) increased nocturnal arterial O(2) saturation by
5% (p < 0.01) and decreased mean nocturnal heart rate by 11% (p < 0.05)
and the number of apnea-hypopnea episodes during sleep by 74% (p <
0=2E05). The decrease in erythropoietin was attributed mainly to the
acetazolamide-induced increase in ventilation and arterial O(2)
saturation. CONCLUSIONS: Acetazolamide, the first efficient
pharmacologic treatment of chronic mountain sickness without adverse
effects, reduces hypoventilation, which may be accentuated during
sleep, and blunts erythropoiesis. Its low cost may allow wide
development with a considerable positive impact on public health in
high-altitude regions.
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
|
| |
|
|